Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations.

Galbiati S, Damin F, Ferraro L, Soriani N, Burgio V, Ronzoni M, Gianni L, Ferrari M, Chiari M.

Cells. 2019 Jul 24;8(8). pii: E769. doi: 10.3390/cells8080769.

2.

Surgical treatment of radial head isolated Mason III fractures.

Strigini G, Rendina M, Ghiara M, Quattrini F, Ghidoni L, Burgio V, Maniscalco P, Benazzo F.

Injury. 2019 Aug;50 Suppl 4:S2-S5. doi: 10.1016/j.injury.2018.11.056. Epub 2019 Mar 19.

PMID:
31133287
3.

Outcomes of music therapy interventions in cancer patients-A review of the literature.

Gramaglia C, Gambaro E, Vecchi C, Licandro D, Raina G, Pisani C, Burgio V, Farruggio S, Rolla R, Deantonio L, Grossini E, Krengli M, Zeppegno P.

Crit Rev Oncol Hematol. 2019 Jun;138:241-254. doi: 10.1016/j.critrevonc.2019.04.004. Epub 2019 Apr 5. Review.

PMID:
31121392
4.

WITHDRAWN: Surgical treatment of radial head isolated Mason III fractures.

Strigini G, Rendina M, Ghiara M, Quattrini F, Ghidoni L, Burgio V, Maniscalco P, Benazzo F.

Injury. 2019 Feb;50(2):382-385. doi: 10.1016/j.injury.2018.11.044. Epub 2018 Dec 5. Erratum in: Injury. 2019 Feb;50(2):R2.

PMID:
30578086
5.

Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.

Damin F, Galbiati S, Soriani N, Burgio V, Ronzoni M, Ferrari M, Chiari M.

PLoS One. 2018 Dec 18;13(12):e0207876. doi: 10.1371/journal.pone.0207876. eCollection 2018.

6.

Evaluation of three advanced methodologies, COLD-PCR, microarray and ddPCR, for identifying the mutational status by liquid biopsies in metastatic colorectal cancer patients.

Galbiati S, Damin F, Burgio V, Brisci A, Soriani N, Belcastro B, Di Resta C, Gianni L, Chiari M, Ronzoni M, Ferrari M.

Clin Chim Acta. 2019 Feb;489:136-143. doi: 10.1016/j.cca.2018.12.004. Epub 2018 Dec 12.

PMID:
30550935
7.

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.

Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A.

ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

8.

CD5+ B cells with the features of subepithelial B cells found in human tonsils.

Dono M, Burgio VL, Colombo M, Sciacchitano S, Reverberi D, Tarantino V, Cutrona G, Chiorazzi N, Ferrarini M.

Eur J Immunol. 2007 Aug;37(8):2138-47.

9.

Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.

Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, Luciani F, Lugini L, Federici C, Ramoni C, Rivoltini L, Parmiani G, Belardelli F, Rivera P, Marcenaro S, Moretta L, Fais S.

Cancer Res. 2004 Jan 1;64(1):378-85.

10.

The human marginal zone B cell.

Dono M, Zupo S, Colombo M, Massara R, Gaidano G, Taborelli G, Ceppa P, Burgio VL, Chiorazzi N, Ferrarini M.

Ann N Y Acad Sci. 2003 Apr;987:117-24. Review.

PMID:
12727630
11.
12.

Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection.

Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y.

Virology. 2002 Dec 20;304(2):187-96.

13.
14.

Structure-function analysis of hepatitis C virus envelope-CD81 binding.

Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, Abrignani S, Grandi G.

J Virol. 2000 May;74(10):4824-30.

15.

Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo.

Cutrona G, Leanza N, Ulivi M, Melioli G, Burgio VL, Mazzarello G, Gabutti G, Roncella S, Ferrarini M.

Blood. 1999 Nov 1;94(9):3067-76.

PMID:
10556191
16.

Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas.

Buonfiglio D, Bragardo M, Bonissoni S, Redoglia V, Cauda R, Zupo S, Burgio VL, Wolff H, Franssila K, Gaidano G, Carbone A, Janeway CA Jr, Dianzani U.

Eur J Immunol. 1999 Sep;29(9):2863-74.

17.

Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2.

Natoli G, Costanzo A, Guido F, Moretti F, Bernardo A, Burgio VL, Agresti C, Levrero M.

J Biol Chem. 1998 Nov 20;273(47):31262-72.

18.

Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology.

Burgio VL, Ballardini G, Artini M, Caratozzolo M, Bianchi FB, Levrero M.

Hepatology. 1998 Jun;27(6):1600-6.

PMID:
9620333
19.

The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar.

Serrano D, Ghiotto F, Roncella S, Airoldi I, Cutrona G, Truini M, Burgio VL, Baroni CD, Ferrarini M, Pistoia V.

Haematologica. 1997 Sep-Oct;82(5):542-9.

20.

The biological relevance of polykaryons in the immune response.

Fais S, Burgio VL, Capobianchi MR, Gessani S, Pallone F, Belardelli F.

Immunol Today. 1997 Nov;18(11):522-7. Review.

PMID:
9386347
21.

The hepatitis B virus X gene induces p53-mediated programmed cell death.

Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M.

Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8162-7.

22.

c-myc proto-oncogene expression by germinal center B cells isolated from human tonsils.

Cutrona G, Dono M, Pastorino S, Ulivi M, Burgio VL, Zupo S, Roncella S, Ferrarini M.

Ann N Y Acad Sci. 1997 Apr 5;815:436-9. No abstract available.

PMID:
9186691
23.

Phenotypic and functional characterization of human tonsillar subepithelial (SE) B cells.

Dono M, Zupo S, Burgio VL, Augliera A, Tacchetti C, Favre A, Grossi CE, Chiorazzi N, Ferrarini M.

Ann N Y Acad Sci. 1997 Apr 5;815:171-81. Review. No abstract available.

PMID:
9186653
24.

MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.

Puri PL, Balsano C, Burgio VL, Chirillo P, Natoli G, Ricci L, Mattei E, Graessmann A, Levrero M.

Oncogene. 1997 Mar 13;14(10):1171-84.

25.

The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein.

Cutrona G, Dono M, Pastorino S, Ulivi M, Burgio VL, Zupo S, Roncella S, Ferrarini M.

Eur J Immunol. 1997 Jan;27(1):234-8.

PMID:
9022024
26.

Subepithelial B cells in the human palatine tonsil. II. Functional characterization.

Dono M, Zupo S, Augliera A, Burgio VL, Massara R, Melagrana A, Costa M, Grossi CE, Chiorazzi N, Ferrarini M.

Eur J Immunol. 1996 Sep;26(9):2043-9.

PMID:
8814244
27.

Subepithelial B cells in the human palatine tonsil. I. Morphologic, cytochemical and phenotypic characterization.

Dono M, Burgio VL, Tacchetti C, Favre A, Augliera A, Zupo S, Taborelli G, Chiorazzi N, Grossi CE, Ferrarini M.

Eur J Immunol. 1996 Sep;26(9):2035-42.

PMID:
8814243
28.

Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease.

Burgio VL, Fais S, Boirivant M, Perrone A, Pallone F.

Gastroenterology. 1995 Oct;109(4):1029-38.

PMID:
7557067
29.

Reactive oxygen intermediates mediate angiotensin II-induced c-Jun.c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells.

Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.

J Biol Chem. 1995 Sep 22;270(38):22129-34.

30.

Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells.

Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.

Ann N Y Acad Sci. 1995 Mar 27;752:394-405. Review.

PMID:
7755283
32.

Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution.

Mauro FR, De Rossi G, Burgio VL, Caruso R, Giannarelli D, Monarca B, Romani C, Baroni CD, Mandelli F.

Haematologica. 1994 Jul-Aug;79(4):334-41.

33.

Characterization of EN4 monoclonal antibody: a reagent with CD31 specificity.

Burgio VL, Zupo S, Roncella S, Zocchi M, Ruco LP, Baroni CD.

Clin Exp Immunol. 1994 Apr;96(1):170-6.

34.

Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.

Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G, et al.

J Immunol. 1994 Mar 15;152(6):3074-87.

PMID:
7511637
35.

Occurrence of a Ki-1-positive anaplastic large-cell lymphoma in a patient with Ph' positive chronic myelogenous leukemia successfully treated by alpha-interferon.

Montefusco E, Lo Coco F, Burgio VL, Rondinelli B, Di Giorgio G, Mancini M, Diverio D, Andriani A, Avvisati G, Alimena G.

Leukemia. 1993 Nov;7(11):1896-9.

PMID:
8231259
36.

Considerations on the prognostic significance of bone marrow micrometastases in breast cancer.

Pecorini F, Veneziano M, Framarino Dei Malatesta ML, Passarello A, Trapani E, Burgio V, Marzetti L.

Eur J Gynaecol Oncol. 1993;14(6):501-5.

PMID:
8181489
37.

Prognostic value of the histologic classification of peripheral T-cell lymphoma: a clinico-pathologic study of 71 HTLV-1 negative cases.

Remotti D, Pescarmona E, Burgio VL, Gastaldi R, Guglielmi C, Martelli M, Mandelli F, Baroni CD.

Leuk Lymphoma. 1992 Nov;8(4-5):371-9.

PMID:
1290962
38.

Expression of ICAM-1, VCAM-1 and ELAM-1 in angiofollicular lymph node hyperplasia (Castleman's disease): evidence for dysplasia of follicular dendritic reticulum cells.

Ruco LP, Gearing AJ, Pigott R, Pomponi D, Burgio VL, Cafolla A, Baiocchini A, Baroni CD.

Histopathology. 1991 Dec;19(6):523-8.

PMID:
1723957
39.

Improved bone marrow biopsy technique.

Burgio VL.

Eur J Haematol. 1991 Oct;47(4):315-6. No abstract available.

PMID:
1954993
40.

Immunohistology of bone marrow: a modified method of glycol-methacrylate embedding.

Burgio VL, Pignoloni P, Baroni CD.

Histopathology. 1991 Jan;18(1):37-43.

PMID:
2013459
41.

Reciprocal translocation involving 3q21 in an unusual myeloproliferative disorder with myelodysplastic features and prominent dysmegakaryopoiesis.

Cedrone M, Mecucci C, Burgio VL, Diverio D, Petti MC, Alimena G.

Cancer Genet Cytogenet. 1991 Jan;51(1):73-8. Review.

PMID:
1984850
42.

Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia.

Cozzolino F, Torcia M, Bettoni S, Aldinucci D, Burgio VL, Petti MC, Rubartelli A, Barbui T, Rambaldi A.

Int J Cancer. 1990 Nov 15;46(5):902-7.

PMID:
1699903
43.

Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients.

Martino P, Venditti M, Micozzi A, Morace G, Polonelli L, Mantovani MP, Petti MC, Burgio VL, Santini C, Serra P, et al.

Rev Infect Dis. 1990 Jul-Aug;12(4):570-82.

PMID:
2385764
44.

[Role of alpha-interferon in the therapy of essential thrombocythemia].

Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio VL, Castello A, Bernasconi C, et al.

Haematologica. 1990 Jul-Aug;75 Suppl 4:41-7. Review. Italian. No abstract available.

PMID:
2074053
45.

Therapy of essential thrombocythemia with alpha-interferon: results and prospects.

Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio VL, Castello A, Bernasconi C, et al.

Eur J Haematol Suppl. 1990;52:15-21. Review.

PMID:
2279539
46.

Candida colonization and systemic infection in neutropenic patients. A retrospective study.

Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, Mandelli F.

Cancer. 1989 Nov 15;64(10):2030-4.

PMID:
2804891
47.

Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.

Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio V, Castello A, Bernasconi C, et al.

Br J Haematol. 1989 Jun;72(2):173-7.

PMID:
2757963
48.

[Recent advances in histiocytosis].

Nespoli L, Aricò M, Burgio VL.

Pediatr Med Chir. 1985 Mar-Apr;7(2):181-8. Italian.

PMID:
3879352
49.

Henoch-Schönlein syndrome and selective IgA deficiency.

Martini A, Ravelli A, Notarangelo LD, Burgio VL, Plebani A.

Arch Dis Child. 1985 Feb;60(2):160-2.

50.

Granule formation in large granular lymphocytes (LGL). Ultrastructural and cytochemical studies on cells from patients with abnormally expanded lgl populations.

Grossi CE, Zicca A, Leprini A, Cadoni A, Pandolfi F, Burgio VL, Romagnani S, Guglielmi C, Ferrarini M.

J Submicrosc Cytol. 1984 Oct;16(4):759-71.

PMID:
6150120

Supplemental Content

Loading ...
Support Center